ConductScience.org, home

Comparison · NCT01837069-9eb8ea5a

Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism. Trial comparisons, record NCT01837069-9eb8ea5a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01837069-9eb8ea5a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.09710.05360.17wilson
Risk in group 20.02110.005790.0735wilson
Risk difference, group 1 minus group 20.0760.007870.15newcombe hybrid score
Risk ratio, group 1 over group 24.611.0420.5log
Odds ratio, group 1 over group 251.0723.4log
Number needed to treat, for one more participant with the outcome on Treatment than on Control13.26.66127from the risk difference interval

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treatment
Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated~Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing~Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing~Atorvastatin: 80mg PO QD at preadmission testing~Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling
10103OG000
Group 2ControlStandard of care295OG001

Outcome

Type
PRIMARY
Title
Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism
Description
Time frame
30 days
Population

Source ClinicalTrials.gov

Trial

Title
Risk Factor Control Before Orthopedic Surgery
NCT number
NCT01837069
Phases
PHASE4
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Lead sponsor
NYU Langone Health
Results first posted
2020-07-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01837069-9eb8ea5a